Ionis Pharmaceuticals, Inc.
IONSNASDAQHealthcare● Active
$74.18
$-0.30(-0.40%)
Market Cap$12.3B
P/E Ratio—
52W High$86.74
52W Low$34.78
Ionis Pharmaceuticals, Inc. (IONS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IONS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
-$0.56
Est. -$0.85 · +34.1%
Revenue
$0.25B
Est. $0.20B · +25.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
IONS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.92 | — | — | — | $0.19B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | -$0.85 | -$0.56 | +34.1% | $0.25B | $0.20B | +25.8% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$1.24 | -$1.41 | -14.0% | $0.20B | $0.16B | +30.1% |
| ▲ Q4 FY2025 | Oct 29, 2025 | -$1.15 | -$0.61 | +47.0% | $0.16B | $0.15B | +2.0% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.27 | $0.86 | +218.5% | $0.45B | $0.13B | +243.1% |
| ▲ Q2 FY2025 | Apr 30, 2025 | -$1.11 | -$0.75 | +32.4% | $0.13B | $0.15B | -12.6% |
| ▲ Q1 FY2025 | Feb 19, 2025 | -$1.09 | -$0.66 | +39.5% | $0.23B | $0.13B | +72.8% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$1.16 | -$0.95 | +18.1% | $0.13B | $0.14B | -7.4% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.92
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
-$0.56
EPS Est.
-$0.85
EPS Surpr.
+34.1%
Revenue
$0.25B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$1.41
EPS Est.
-$1.24
EPS Surpr.
-14.0%
Revenue
$0.20B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
-$0.61
EPS Est.
-$1.15
EPS Surpr.
+47.0%
Revenue
$0.16B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.86
EPS Est.
$0.27
EPS Surpr.
+218.5%
Revenue
$0.45B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
-$0.75
EPS Est.
-$1.11
EPS Surpr.
+32.4%
Revenue
$0.13B
Q1 FY2025
Feb 19, 2025Beat
EPS Actual
-$0.66
EPS Est.
-$1.09
EPS Surpr.
+39.5%
Revenue
$0.23B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.95
EPS Est.
-$1.16
EPS Surpr.
+18.1%
Revenue
$0.13B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.10 | $0.12 | $0.14 | 2 |
| Q3 FY2027 | $-0.11 | $-0.10 | $-0.08 | 1 |
| Q2 FY2027 | $-0.52 | $-0.45 | $-0.36 | 1 |
| Q1 FY2027 | $-0.84 | $-0.74 | $-0.59 | 2 |
| Q4 FY2026 | $-1.04 | $-0.91 | $-0.73 | 2 |
| Q3 FY2026 | $-1.10 | $-1.08 | $-1.05 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.4B | $0.5B | $0.6B | 7 |
| Q3 FY2027 | $0.3B | $0.4B | $0.4B | 8 |
| Q2 FY2027 | $0.3B | $0.3B | $0.3B | 7 |
| Q1 FY2027 | $0.2B | $0.3B | $0.3B | 11 |
| Q4 FY2026 | $0.2B | $0.3B | $0.3B | 11 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 14 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +34.1% | $71.78 | $74.83 | +4.25% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -14.0% | $85.45 | $80.93 | -5.29% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +47.0% | $73.57 | $71.88 | -2.30% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +218.5% | $41.48 | $43.37 | +4.56% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +32.4% | $29.81 | $30.71 | +3.02% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +39.5% | $31.95 | $31.81 | -0.44% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +18.1% | $38.80 | $39.04 | +0.62% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +51.1% | $49.46 | $51.32 | +3.76% |
Q2 FY2026+4.25%
Report Date
Apr 29, 2026
EPS Beat/Miss
+34.1%
Price Before
$71.78
Price After
$74.83
Q1 FY2026-5.29%
Report Date
Feb 25, 2026
EPS Beat/Miss
-14.0%
Price Before
$85.45
Price After
$80.93
Q4 FY2025-2.30%
Report Date
Oct 29, 2025
EPS Beat/Miss
+47.0%
Price Before
$73.57
Price After
$71.88
Q3 FY2025+4.56%
Report Date
Jul 30, 2025
EPS Beat/Miss
+218.5%
Price Before
$41.48
Price After
$43.37
Q2 FY2025+3.02%
Report Date
Apr 30, 2025
EPS Beat/Miss
+32.4%
Price Before
$29.81
Price After
$30.71
Q1 FY2025-0.44%
Report Date
Feb 19, 2025
EPS Beat/Miss
+39.5%
Price Before
$31.95
Price After
$31.81
Q4 FY2024+0.62%
Report Date
Nov 6, 2024
EPS Beat/Miss
+18.1%
Price Before
$38.80
Price After
$39.04
Q3 FY2024+3.76%
Report Date
Aug 1, 2024
EPS Beat/Miss
+51.1%
Price Before
$49.46
Price After
$51.32
Avg Beat Reaction+1.92%
Avg Miss Reaction-5.29%
Beat Rate7 / 8 quarters
Largest Move-5.29% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IONS ends December
Ionis Pharmaceuticals, Inc. (IONS) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $-0.56 — beating the analyst consensus of $-0.85 by +34.1%. The next IONS earnings date is expected around September 1, 2026.
Each quarter, investors track IONS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IONS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IONS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IONS earnings · 5 questionsIonis Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. IONS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IONS historically reports after market close (AMC).
IONS earnings datewhen is IONS earningsIONS next earnings datewhen does IONS report earningsIONS earnings calendar
▸ Source: FMP · Ionis Pharmaceuticals, Inc. SEC filings · US GAAP · Ionis Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026